Interpreting thresholds for a clinically significant change in health status in asthma and COPD.
about
Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS)Yoga for asthmaIndacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary diseaseLong-acting beta 2 -agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary diseaseNon-invasive ventilation during exercise training for people with chronic obstructive pulmonary diseaseBronchial thermoplasty for moderate or severe persistent asthma in adultsCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary diseaseBronchial thermoplasty for moderate or severe persistent asthma in adultsCombined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary diseaseCombined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseLung volume reduction surgery for diffuse emphysemaInhaled corticosteroids for stable chronic obstructive pulmonary diseaseValue of supplemental interventions to enhance the effectiveness of physical exercise during respiratory rehabilitation in COPD patients. A systematic reviewRespiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality -- a systematic reviewHealth-related quality of life is related to COPD disease severityImproving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterolThe psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature reviewSupported self-management for patients with COPD who have recently been discharged from hospital: a systematic review and meta-analysisInterpreting patient-reported outcomes from clinical trials in COPD: a discussionHigh morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: under-recognised phenomenaDescriptive analysis of the respiratory health status of persons exposed to Libby amphibole asbestosOutcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitationsOximetry-supported self-management for chronic obstructive pulmonary disease: mixed method feasibility pilot project.Integrating health status and survival data: the palliative effect of lung volume reduction surgery.Health status in COPD: current data and future trends.Action Plan to enhance self-management and early detection of exacerbations in COPD patients; a multicenter RCTEvaluation of a combined strategy directed towards health-care professionals and patients with chronic obstructive pulmonary disease (COPD): information and health education feedback for improving clinical monitoring and quality-of-life.Magnitude of exercise capacity and quality of life improvement following repeat pulmonary rehabilitation in patients with COPDDeterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry.Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD?Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.Reporting FDR analogous confidence intervals for the log fold change of differentially expressed genes.Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scoresPsychosocial risk factors for hospital readmission in COPD patients on early discharge services: a cohort studyEfficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: phase III study resultsTasmanian Aborigines step up to health: evaluation of a cardiopulmonary rehabilitation and secondary prevention program.Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients' perceived onset of effectAssessing health status in COPD. A head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ).Prevalence and correlations with depression, anxiety, and other features in outpatients with chronic obstructive pulmonary disease in China: a cross-sectional case control study.American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation.
P2860
Q21245611-D1F8762D-800E-4278-90B9-04022A6B7393Q24185858-D7F74B0C-253F-422E-A257-03DBBC1F6712Q24186652-5CCD992B-D2F7-4B4F-B217-FDCA6D9D95DCQ24194044-3F50E0E3-245D-47D5-AED3-340448440861Q24194665-26BAFE49-0A41-48BF-A8F2-7135241E83B5Q24198119-48C93E0A-94EA-41E9-A1AF-11706BFF723DQ24199130-96D89999-4564-448D-8077-05C49055D0CBQ24202251-C02B9DD5-4DDD-4C78-9373-B71DF718C8B8Q24243515-234A286F-82DD-4273-A459-46B01068BADFQ24243564-ECE6C5CF-A7FB-4064-8991-1C165DFD638CQ24244372-2B35DAA4-D445-44CA-B627-CD3D8D096B3CQ24245481-1C8108CD-7D6D-4160-B340-01BFD44CDE20Q24791899-F27E2570-3512-482A-A8DC-28FE5915ACACQ24814417-D633519C-3959-4EBD-99AA-DCD18C246082Q24814864-8275CB4A-89B3-45FE-AD17-B91AD1A6B2E4Q26851664-82EBB52F-B3C9-4EFF-B99F-251DF5FE07ABQ26992007-6ADC9F4E-047E-400B-A29D-48CC4DED7FFBQ27004225-BA7566CD-A359-4837-AC1D-52B1D3D464DBQ28072901-0E9AD261-4425-4258-BD0B-BDC2EAE0D7E3Q28391941-3217AFC5-F13F-4A1C-AF1F-16F10BDFE484Q29248579-99570E8B-75F1-4366-8DB0-E72DB1A196E7Q30480535-D39BBDD6-C526-4394-BEB3-E1CA29632253Q30670891-A52169CE-A01D-4E14-8FB1-DFE00C69E85FQ33456631-77C388CA-9752-402D-AC8C-D337BD554868Q33508897-6E90E816-DF4C-44AA-9241-D5C4FD15FC44Q33521100-CAA081B1-EAB9-49E1-AE97-AB72C6832A38Q33529282-CCA23339-1A48-4632-80D1-329FB817B25AQ33553576-21476A6D-1D9E-4BE4-9E4C-B7F48F956A2AQ33713789-02349A99-C4A4-450A-808E-99C6707A979FQ33878940-75B50E49-6EE4-4243-8F92-2BBC39D5FC95Q33901651-D6F054F7-6CF6-4734-AA4C-D7090E0D1C45Q33960941-5641F4DA-FB18-492B-87EB-3D7FCC1E954CQ33991002-71AAC489-6BDF-472F-AFAD-E7CF6CB1CAA3Q34067576-04730733-82A4-4A8A-9E4E-6067B16BDFA3Q34074832-2EFB271D-4C20-4403-96DF-6D49A00D43D3Q34076598-3EF1720B-E75F-4EC5-A096-F38EF777F759Q34154974-8F5E35B3-4F32-40BA-BFC7-DD7EF6144D14Q34274535-56363A05-D664-4B59-931A-C41C2499F60FQ34408809-8488F157-0D5D-446D-9C65-4DBA032A5848Q34535807-CD1874D6-C492-4150-AA10-316D3F874737
P2860
Interpreting thresholds for a clinically significant change in health status in asthma and COPD.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Interpreting thresholds for a ...... lth status in asthma and COPD.
@ast
Interpreting thresholds for a ...... lth status in asthma and COPD.
@en
Interpreting thresholds for a ...... lth status in asthma and COPD.
@nl
type
label
Interpreting thresholds for a ...... lth status in asthma and COPD.
@ast
Interpreting thresholds for a ...... lth status in asthma and COPD.
@en
Interpreting thresholds for a ...... lth status in asthma and COPD.
@nl
prefLabel
Interpreting thresholds for a ...... lth status in asthma and COPD.
@ast
Interpreting thresholds for a ...... lth status in asthma and COPD.
@en
Interpreting thresholds for a ...... lth status in asthma and COPD.
@nl
P1476
Interpreting thresholds for a ...... lth status in asthma and COPD.
@en
P2093
P304
P356
10.1183/09031936.02.00063702
P577
2002-03-01T00:00:00Z